TSVT - Leerink ups 2seventy to outperform cites attractiveness as takeover target
2024-01-31 15:47:11 ET
More on 2seventy bio
- 2seventy bio: An Overload Of Troubles At This Small Pharma
- 2seventy bio, Inc. (TSVT) Q3 2023 Earnings Call Transcript
- 2seventy stock rises as Regeneron acquires R&D assets
- Bristol-Myers Squibb wins EU nod for expanded Abecma indication
- Seeking Alpha’s Quant Rating on 2seventy bio